CSL889_2001: A phase 2/phase 3, multicenter, randomized, multiple-dose, double-blind, placebo-controlled adaptive study to evaluate the safety, efficacy and pharmacokinetics of CSL889 in adults and adolescents with sickle cell disease during VOC